-
We all know, clinical research generates enormous volumes of data. And these volumes continue to grow.
Every completed study contains detailed information on endpoints, eligibility criteria, enrollment performance, adverse events, dosing strategies, and operational outcomes. Yet once a trial closes and regulatory submissions are complete, much of that data becomes archival.
It sits in repositories. It is referenced occasionally. It is rarely treated as an active design asset.
This is beginning to change.
Reverse translation, the practice of feeding insights from completed clinical trials back into earlier stages of development, offers a powerful opportunity to improve future study design.
Mar 31, 2026
-
The first study visit sets the tone for everything that follows.
For patients, screening is their introduction to clinical research. It is where expectations are formed, trust is built, and burden becomes real. For sites, it is often one of the most resource-intensive moments in the trial lifecycle.
Yet screening visits have steadily grown longer and more complex.
Additional laboratory panels, imaging requirements, multiple questionnaires, device training sessions, and layered consent discussions can turn what was once a straightforward evaluation into a multi-hour commitment. In some studies, screening stretches across multiple visits over several weeks.
The impact is rarely neutral.
Mar 26, 2026
-
Model-informed approaches are gaining traction across clinical development.
Among them, disease progression modeling has attracted increasing attention. When applied thoughtfully, it can help sponsors design more efficient trials, select more sensitive endpoints, and make better-informed go or no-go decisions.
But like any tool, disease progression modeling works best when used for the right questions.
Understanding when to use it, and when it adds limited value, is critical.
Mar 24, 2026
-
We track biomarkers with precision. We analyze endpoints with statistical rigor. We monitor safety signals in real time.
Yet when it comes to measuring the patient experience of participating in a trial, the approach is often informal, inconsistent, or reactive.
That gap is becoming harder to justify.
If patient centricity is a serious goal in modern clinical development, then patient feedback must be measured with the same discipline applied to clinical endpoints.
Mar 19, 2026
-
Eligibility criteria sit at the center of every clinical trial.
They define who can participate, shape safety parameters, influence statistical power, and signal scientific intent. They also quietly determine how difficult enrollment will be and how representative the study population becomes.
For years, eligibility criteria have been built largely on precedent, clinical caution, and competitive positioning. Today, sponsors have the ability to test those criteria against real-world populations before a protocol is finalized.
That shift is changing how feasibility is defined.
Mar 17, 2026
-
Clinical trial design has always relied on models.
Power calculations estimate sample size. Pharmacokinetic and pharmacodynamic models inform dosing. Simulations project enrollment timelines. Assumptions about disease progression shape endpoint selection and study duration.
What is changing is the depth, integration, and accessibility of modeling across the development lifecycle.
Mar 12, 2026
-
When protocols become overly complex, they can slam the brakes on study progress. But this kind of complexity does not arrive all at once. It accumulates.
A biomarker is added in case it becomes important later. An extra imaging timepoint is included to capture more detail. Each addition feels reasonable. Each has a defensible rationale.
Over time, however, this “just-in-case” approach can transform a focused study into an operational burden.
Mar 10, 2026
-
For decades, clinical research has struggled with a familiar problem. The patients most affected by certain diseases are often the least represented in clinical trials.
They may be underdiagnosed. They may not be connected to specialty care. They may face stigma, geographic barriers, or distrust of the healthcare system. Some are digitally active but invisible to traditional site-based recruitment strategies. Others interact with healthcare intermittently and never encounter a clinical trial conversation.
These patients are frequently labeled as “hard to reach.”
A more accurate description may be this: they are being reached in the wrong way.
Mar 5, 2026
-
Agentic AI is emerging as a response to the operational realities of clinical trials. Rather than simply presenting data, these systems are designed to interpret signals, recommend next steps, and coordinate actions across existing platforms.
Mar 3, 2026
-
Clinical trial protocols are often built on a careful balance of scientific rigor, competitive positioning, regulatory precedent, and historical templates. On paper, they can look precise and defensible. In practice, they sometimes describe a patient population that barely exists outside the protocol itself.
This disconnect between protocol assumptions and real-world clinical practice is one of the most persistent drivers of enrollment delays and representativeness gaps. As real-world data becomes more accessible and more actionable, sponsors have an opportunity to narrow that gap before a study ever launches.
Feb 26, 2026
-
Clinical trials are collecting more data than ever before.
Across therapeutic areas, protocols have grown denser: more endpoints, more exploratory analyses, more biomarker sampling, more patient-reported outcomes, more frequent assessments. In many Phase II and III studies, the total number of data points now reaches into the millions.
The question is no longer whether we can collect this volume of data. It’s whether we should.
Feb 24, 2026
-
For years, clinical trial innovation has advanced along parallel tracks.
Patient engagement teams worked to bring lived experience into protocol development. Data science teams built increasingly sophisticated real-world evidence models. Technology leaders explored automation and artificial intelligence to streamline operations.
Today, those tracks are beginning to converge.
Feb 19, 2026
-
Artificial intelligence is quickly reshaping the way clinical trials are designed and executed, promising gains in efficiency, insight, and agility. But one of the less obvious, and yet critically important, opportunities for AI lies not in automating tasks, but in promoting equity across clinical research. This means moving beyond raw performance metrics to ensure that AI systems help reduce systemic bias, broaden representation, and strengthen the scientific validity of trials for all patients.
Feb 17, 2026
-
SCOPE is proud to announce the recipient of the 2026 SCOPE Site Innovation Award, recognizing creativity and impact in solutions that reduce site burden, improve trial execution, and strengthen the site perspective in clinical research operations. This award highlights innovations that deliver practical, measurable improvements to site workflows, participant access, and trial connectivity, offering models that other organizations can learn from and adopt
Feb 3, 2026
-
SCOPE is pleased to announce the recipients of the 2026 SCOPE Participant Engagement Award, recognizing impactful, patient-centered approaches that strengthen education, trust, and engagement in clinical research.
The 2026 award honors Biogen, Proximity Health Solutions, and BlackDoctor.org for their collaborative initiative, Better Together – Sharing Our Lupus Stories.
Feb 3, 2026
-
Clinical endpoints are evolving. Patient-reported outcomes, clinician assessments, and data from connected devices are now central to how many trials measure safety and efficacy. Yet these data streams are often collected and analyzed separately, limiting their value and delaying insight. Integrating clinical outcomes assessments (COAs) with device data at the point of capture is changing how endpoints support both science and operations.
Jan 28, 2026
-
Electronic clinical outcome assessments have been part of clinical trials for years, yet many teams still experience them as one of the most operationally challenging components of study setup and execution. Despite advances in technology, the same friction points continue to surface across studies. This has led to growing interest in whether AI can finally simplify eCOA workflows, and where its limits remain.
Jan 28, 2026
-
Feasibility has long been one of the most consequential, and most fragile, stages of clinical trial planning. Decisions about where to run a study and which sites to involve shape everything that follows, from enrollment speed to data quality to overall timelines. Yet feasibility has traditionally relied on limited historical experience, manual surveys, and assumptions that don’t always hold once a trial is underway.
Jan 28, 2026
-
AI is often introduced into clinical development through small, targeted pilots. A tool to assist with protocol drafting, a model to improve enrollment forecasting, or an automation to speed document generation. These efforts can deliver real value, but on their own, they rarely change how trials are run at scale. Industrializing clinical trials with AI requires a broader shift, one that connects these capabilities into a coherent, end-to-end approach.
Jan 28, 2026
-
Clinical trial planning has always involved a fair amount of uncertainty. Protocol assumptions are made months, sometimes years, before a study begins, often with limited visibility into how real-world conditions will evolve. Once execution starts, teams are left adjusting plans on the fly, reacting to delays, competition for sites, and shifting priorities. Decision intelligence and digital twin approaches are changing that dynamic by allowing teams to test decisions before those decisions carry real-world consequences.
Jan 28, 2026